Diphtheria toxoid
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
1996
- First approval year
- 1996
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Diphtheria toxoid
- diphtheria toxoid component of hexacima
- Diphtheria toxoid component of hexacima
- diphtheria toxoid component of hexavac
- Diphtheria toxoid component of hexavac
- diphtheria toxoid component of hexyon
- Diphtheria toxoid component of hexyon
- diphtheria toxoid component of infanrix hepb
- Diphtheria toxoid component of infanrix hepb
- diphtheria toxoid component of infanrix hexa
- Diphtheria toxoid component of infanrix hexa
- diphtheria toxoid component of infanrix penta
- Diphtheria toxoid component of infanrix penta
- diphtheria toxoid component of primavax
- Diphtheria toxoid component of primavax
- diphtheria toxoid component of quintanrix
- Diphtheria toxoid component of quintanrix
- diphtheria toxoid component of triacelluvax
- Diphtheria toxoid component of triacelluvax
- diphtheria toxoid component of tritanrix hepb
- Diphtheria toxoid component of tritanrix hepb
- diphtheria toxoid component of vaxelis
- Diphtheria toxoid component of vaxelis
- diphtheria toxoid
- Diphtheria toxoid
- tetanus toxoid diphtheria toxoid and pertussis vaccine
- Tetanus-Diphtheria Toxoid (Td)
- ATC classification codes
- J07AF01
Sources for recorded values
- ChEMBL ID
- CHEMBL2109121
- RxNorm IDs (RxCUI)
- 798304
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Diphtheria toxoid vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Diphtheria toxoid
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Glioblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Alopecia Areata
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004192
- Subject identifier
- D000506
- Condition
- Severe Dengue
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004227
- Subject identifier
- D019595
- Condition
- Meningococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004249
- Subject identifier
- D008589
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Dengue
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005547
- Subject identifier
- D003715
- Condition
- Tetanus
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005593
- Subject identifier
- D013742
- Condition
- Meningitis, Meningococcal
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001040
- Subject identifier
- D008585
- Condition
- Brain Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0001657
- Subject identifier
- D001932
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000650
- Condition identifier
- EFO_0004192
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004197
- Condition identifier
- EFO_0004227
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004249
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005549
- Condition identifier
- EFO_0005593
- Condition identifier
- EFO_0007450
- Condition identifier
- EFO_0009444
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001040
- Highest recorded phase
- 3
- Condition identifier
- HP_0001662
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004948
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005077
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005344
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005504
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005526
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0017373
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0018177
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0021042
- Highest recorded phase
- 2
Reported adverse events
- Event
- vertical infection transmission
- Reports
- 1
- Reporting signal score
- 8.39775
- NCT00993447
- NCT01187433
- NCT02992418
- NCT01519713
- NCT02752906
- NCT02842853
- NCT06131554
- NCT02193347
- NCT02518555
- NCT03691610
- NCT04143061
- NCT03927222
- NCT04006457
- Dose
- 0.5 mL
- Route
- Intramuscular
- How often
- At 2, 4, 6, and 15-18 months of age
- Discard unused portion
- Reconstitute immediately before administration
- Use immediately after reconstitution
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (172)
- A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)
- A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
- A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
- A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)
- A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
- A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
- A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
- A First in Human Study Investigating the Safety of an Unloaded and Loaded (With a Tetanus-containing Vaccine Booster) Microneedle Patch in Healthy Adults
- A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
- A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
- A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study
- A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.
- A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine
- A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
- A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
- A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants
- A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India
- A Study to Assess the Safety of Adacel® Vaccine
- A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants
- A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.
Approved for (1)
In development for (8)
- Alopecia areata Phase 3
- B-cell chronic lymphocytic leukemia Phase 2
- Brain cancer Phase 1
- Dengue disease Phase 3
- Dengue hemorrhagic fever Phase 3
- Glioblastoma Phase 2
- Meningococcal infection Phase 3
- Meningococcal meningitis Phase 3